| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/23/1999 | WO1999047507A2 1,3,4-thiadiazoles useful for the treatment of cmv infections |
| 09/23/1999 | WO1999047506A1 Cyclooctadepsipeptides and their use for combating endoparasites |
| 09/23/1999 | WO1999047505A1 Phthalazinone pde iii/iv inhibitors |
| 09/23/1999 | WO1999047504A1 Novel histidine derivatives preparation method and uses |
| 09/23/1999 | WO1999047502A1 Cytotoxic metal chelators and methods for making and using same |
| 09/23/1999 | WO1999047501A2 Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection |
| 09/23/1999 | WO1999047490A1 Bicyclo[2.2.1]heptanes and related compounds |
| 09/23/1999 | WO1999047179A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 09/23/1999 | WO1999047175A1 Pharmaceutical compositions containing melatonin inclusion complexes |
| 09/23/1999 | WO1999047171A1 Combination of a gaba-a alpha 5 inverse agonist and a muscarinic agonist |
| 09/23/1999 | WO1999047162A1 Products in the treatment of cancer |
| 09/23/1999 | WO1999047153A2 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS |
| 09/23/1999 | WO1999047149A1 Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament without uterotropic effects |
| 09/23/1999 | WO1999047148A1 Composition from ginkgo biloba leaves, preparation and uses |
| 09/23/1999 | WO1999047145A1 Use of sphingosin-1-phosphate, sphingosin-1-phosphate derivatives and/or mixtures thereof for the treatment of inflammatory diseases of the skin |
| 09/23/1999 | WO1999047144A1 Method and means for treating glomerulonephritis |
| 09/23/1999 | WO1999047143A1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 09/23/1999 | WO1999047142A1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist |
| 09/23/1999 | WO1999047141A1 Method of treating skin irritation |
| 09/23/1999 | WO1999047140A1 Topical antiseptic compositions and methods |
| 09/23/1999 | WO1999047139A1 Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations |
| 09/23/1999 | WO1999047138A1 Statin-matrix metalloproteinase inhibitor combinations |
| 09/23/1999 | WO1999047137A1 Preparations containing licariin |
| 09/23/1999 | WO1999047136A1 Prevention and treatment of adhesions |
| 09/23/1999 | WO1999047135A1 Conjugated linoleic acid compositions |
| 09/23/1999 | WO1999047134A1 Keto acid salts and amine derivatives, and their use for preparing medicines |
| 09/23/1999 | WO1999047133A1 Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage |
| 09/23/1999 | WO1999047132A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 09/23/1999 | WO1999047131A2 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor |
| 09/23/1999 | WO1999047128A1 Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 09/23/1999 | WO1999047125A1 Controlled release oral tablet having a unitary core |
| 09/23/1999 | WO1999047123A1 Pharmaceutical composition containing a statin and aspirin |
| 09/23/1999 | WO1999047120A1 Ophthalmic solution comprising glycogen |
| 09/23/1999 | WO1999047119A1 Methods for regulating skin appearance |
| 09/23/1999 | WO1999047118A1 Compositions for regulating skin appearance |
| 09/23/1999 | WO1999047112A1 Method of reducing cellulite in mammalian skin |
| 09/23/1999 | WO1999047101A2 Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof |
| 09/23/1999 | WO1999046988A1 Compositions and methods for antigen-specific vaccination |
| 09/23/1999 | WO1999046987A1 Disinfecting composition |
| 09/23/1999 | WO1999040944A3 Hydroxylation activated drug release |
| 09/23/1999 | WO1999040905A3 Use of hyperforin and hyperforin-containing extracts in the treatment and prophylaxis of dementing diseases |
| 09/23/1999 | WO1999039740A8 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 09/23/1999 | WO1999039736A3 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES |
| 09/23/1999 | WO1999039728A3 Methods of inducing hair growth and coloration |
| 09/23/1999 | WO1999039694A3 Compositions containing organic compounds |
| 09/23/1999 | WO1999039682A3 Lipid mixtures and their use |
| 09/23/1999 | WO1999038821A3 Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications |
| 09/23/1999 | WO1999038480A3 Antiplaque oral composition and method |
| 09/23/1999 | WO1999036100A3 Polymeric carrier |
| 09/23/1999 | WO1999036030A3 Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions |
| 09/23/1999 | WO1999033859A9 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 09/23/1999 | WO1999033847A9 Phosphinic alkanoic acid derivatives |
| 09/23/1999 | WO1999033468A9 Method for treating hyperoxia |
| 09/23/1999 | WO1999033463A9 SESQUITERPENE LACTONES SPECIFICALLY INHIBIT ACTIVATION OF NF-λB BY PREVENTING THE DEGRADATION OF IλB-α AND IλB-$g(b) |
| 09/23/1999 | WO1999032620A9 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 09/23/1999 | WO1999025327A3 Small molecule intervention in hiv-1 replication |
| 09/23/1999 | WO1999017755A3 Medicaments |
| 09/23/1999 | WO1999015157A3 G2 checkpoint inhibitors and assay |
| 09/23/1999 | WO1999012531A3 Hormonal contraceptive |
| 09/23/1999 | WO1999010320A8 Substituted benzene compounds as antiproliferative and cholesterol lowering agents |
| 09/23/1999 | DE19813839A1 Human nucleic acid sequences and protein products from tumor breast tissue, useful for breast cancer therapy |
| 09/23/1999 | DE19812331A1 New benzo-heterocyclic substituted piperidine derivatives useful as excitatory aminoacid receptor antagonists, used e.g. for treating neurodegenerative diseases |
| 09/23/1999 | DE19811683A1 Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease |
| 09/23/1999 | DE19811559A1 New substituted derivatives of cyclooctadepsipeptide PF1022, useful as parasiticides, especially anthelmintics |
| 09/23/1999 | DE19810336A1 Thioctic acid useful for pharmaceutical, cosmetic and nutritional purposes e.g. as an analgesic, antiinflammatory or antioxidant |
| 09/23/1999 | DE19802139C1 Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung A monoclonal antibody specific for activated coagulation factor VII and its use |
| 09/23/1999 | DE19739763A1 Vitamin preparation for treating various diseases e.g. depression, itching and stroke |
| 09/23/1999 | CA2625284A1 Modulators of the function of receptors of the tnf/ngf receptor family |
| 09/23/1999 | CA2324337A1 Products in the treatment of cancer |
| 09/23/1999 | CA2324270A1 Hypnotic .beta.-carboline derivatives, process for their preparation and their use as medicinal products |
| 09/23/1999 | CA2324237A1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist |
| 09/23/1999 | CA2323897A1 Suicide gene therapy system for the treatment of brain tumours |
| 09/23/1999 | CA2323896A1 Crystalline form of paroxetine |
| 09/23/1999 | CA2323887A1 Use of sphingosin-1-phosphate, sphingosin-1-phosphate derivatives and/or mixtures thereof for the treatment of inflammatory diseases of the skin |
| 09/23/1999 | CA2323783A1 Benzenesulfonamide-derivatives and their use as medicaments |
| 09/23/1999 | CA2323771A1 Phthalazinone pde iii/iv inhibitors |
| 09/23/1999 | CA2323637A1 Modulators of the function of receptors of the tnf/ngf receptor family and other proteins |
| 09/23/1999 | CA2323628A1 Cyclooctadepsipeptides and their use for combating endoparasites |
| 09/23/1999 | CA2323618A1 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor |
| 09/23/1999 | CA2323418A1 Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection |
| 09/23/1999 | CA2323364A1 Compositions for regulating skin appearance |
| 09/23/1999 | CA2323238A1 Methods and compositions for diagnosis of rheumatoid arthritis |
| 09/23/1999 | CA2323181A1 Methods for regulating skin appearance |
| 09/23/1999 | CA2323179A1 Method of reducing cellulite in mammalian skin |
| 09/23/1999 | CA2323093A1 Compounds and methods for therapy and diagnosis of lung cancer |
| 09/23/1999 | CA2323083A1 Isolated mammalian membrane protein genes and related reagents |
| 09/23/1999 | CA2322994A1 Topical antiseptic compositions and methods |
| 09/23/1999 | CA2322742A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/23/1999 | CA2322699A1 Compositions and methods for enhanced antigen delivery to antigen presenting cells in vivo |
| 09/23/1999 | CA2322659A1 Compositions and methods for gene-based vaccines to provoke t cell responses |
| 09/23/1999 | CA2321155A1 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 09/23/1999 | CA2320167A1 1,3,4-thiadiazoles useful for the treatment of cmv infections |
| 09/23/1999 | CA2319493A1 Heterocyclic signal transduction inhibitors, compositions containing them |
| 09/23/1999 | CA2317796A1 Method and means for treating glomerulonephritis |
| 09/23/1999 | CA2309588A1 Statin-matrix metalloproteinase inhibitor combinations |
| 09/23/1999 | CA2289621A1 Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase) |
| 09/23/1999 | CA2249662A1 Novel compounds |
| 09/22/1999 | EP0943684A2 Frizzled-like polypeptides and polynucleotides |
| 09/22/1999 | EP0943683A1 Human vanilloid receptor homologue Vanilrep1 |
| 09/22/1999 | EP0943680A1 Suicide gene therapy system for the treatment of brain tumours |